The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...
Tirzepatide, a weekly GLP-1 and GIP drug sold under the brand name Zepbound, produced weight loss of up to 17.8% after 72 weeks, the analysis found. REUTERS McGill researchers are calling for more ...
A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...
Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...
Zepbound is an injectable prescription medication ... The medication also promotes weight loss, with patients losing an average of 45 pounds or 18% of their body weight, during the trials.
The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive sleep apnea (OSA) in individuals with obesity.
The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the ...